MTARC1 and metabolic dysfunction-associated steatohepatitis: Carrying this variant is associated with an improved lipidprofile and a corresponding protective effect against MASLD and MASH.26,35 Therefore, the specific targeting of mARC1 appears to be a moredesirable approach at this stage for treatment in liver diseases.